Rogers is positioned to collaborate with leaders in the field to explore treatment enhancement with the addition of high-precision, non-invasive stimulation therapy provided by new and improved transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS).
Our Research teams are exploring CBM (Cognitive Bias Modification) Application in OCD and beyond. Other research foci include collaborative trialing of Selective Serotonin Reuptake Inhibitors (SSRI) and the function and effects of sleep quality in recovery.
Rogers’ growing data infrastructure uniquely positions us to use complex sets of variables to understand our patients at an individual level. Using the power of population-level datasets, we can derive impactful insights into mental health and addiction prediction and treatment strategies. Rogers has long had an interest in creating and employing algorithms to improve the delivery and efficacy of treatment and predict outcomes. Currently, Rogers is utilizing a suicide risk prediction algorithm which was developed internally.
Our vision is to develop real-time models to provide increasingly refined clinical decision support and treatment response predictions.
We are currently exploring telehealth delivery and efficacy and looking forward to expanding our scope of research.
Genetics research is an important path toward advanced diagnostics, risk prediction, personalized medicine, and treatment enhancement strategies. Rogers is creating a phenotype-enhanced behavioral health biobank. This dataset will be the first of its kind to include both genotype and phenotype via our item-level patient-reported outcomes data utilizing ROAS (Rogers Online Assessment System). Developed in 2012 specifically for Rogers, ROAS is utilized to assign, manage, and track self-reported clinical assessments.
Rogers’ Research Center Biobank will not only contribute critical data to advance research for the special populations it serves, but also provide treatment teams with vital information about genetic and other molecular factors impacting treatment outcomes of individual patients.